Ionis Pharmaceuticals Inc
IONS80.130USD
-1.410-1.73%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
12.91BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ionis Pharmaceuticals Inc Unternehmen
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc Informationen
BörsenkürzelIONS
Name des UnternehmensIonis Pharmaceuticals Inc
IPO-datumMay 17, 1991
CEOMonia (Brett P)
Anzahl der mitarbeiter1069
WertpapierartOrdinary Share
GeschäftsjahresendeMay 17
Addresse2855 Gazelle Court
StadtCARLSBAD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92010
Telefon17609319200
Websitehttps://www.ionis.com/
BörsenkürzelIONS
IPO-datumMay 17, 1991
CEOMonia (Brett P)
Führungskräfte von Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Mar 4
Währung: USDAktualisiert: Tue, Mar 4
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Aktionärsstatistik
Aktualisiert: Wed, Nov 19
Aktualisiert: Wed, Nov 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Andere
50.79%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Andere
50.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
68.58%
Investment Advisor/Hedge Fund
19.53%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
841
178.22M
110.03%
-6.52M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
23.69M
14.63%
+46.05K
+0.19%
Sep 30, 2025
Capital World Investors
17.96M
11.09%
+5.24M
+41.17%
Dec 31, 2025
The Vanguard Group, Inc.
16.44M
10.15%
-235.68K
-1.41%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
13.16M
8.12%
-2.89M
-18.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.45M
5.22%
-272.23K
-3.12%
Sep 30, 2025
Wellington Management Company, LLP
6.59M
4.07%
+243.03K
+3.83%
Sep 30, 2025
Bellevue Asset Management AG
6.24M
3.86%
-1.61M
-20.49%
Sep 30, 2025
State Street Investment Management (US)
4.39M
2.71%
-141.75K
-3.13%
Sep 30, 2025
Deep Track Capital LP
3.81M
2.35%
-1.08M
-22.15%
Sep 30, 2025
Two Sigma Investments, LP
3.65M
2.25%
-806.92K
-18.11%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil5.24%
ARK Genomic Revolution ETF
Anteil4.11%
Virtus LifeSci Biotech Products ETF
Anteil3.34%
Franklin Genomic Advancements ETF
Anteil2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.57%
First Trust Health Care Alphadex Fund
Anteil2.47%
VanEck Morningstar SMID Moat ETF
Anteil2.38%
WisdomTree BioRevolution Fund
Anteil2.28%
State Street SPDR S&P Biotech ETF
Anteil2.28%
Capital Group US Small and Mid Cap ETF
Anteil2.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Ionis Pharmaceuticals Inc sind:
Fidelity Management & Research Company LLC hält 23.69M Aktien, was 14.63% der Gesamtaktien entspricht.
Capital World Investors hält 17.96M Aktien, was 11.09% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 16.44M Aktien, was 10.15% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 13.16M Aktien, was 8.12% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.45M Aktien, was 5.22% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 23.69M Aktien, was 14.63% der Gesamtaktien entspricht.
Capital World Investors hält 17.96M Aktien, was 11.09% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 16.44M Aktien, was 10.15% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 13.16M Aktien, was 8.12% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.45M Aktien, was 5.22% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Ionis Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Ionis Pharmaceuticals Inc sind:
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
Wie viele Institutionen halten Anteile an Ionis Pharmaceuticals Inc (IONS)?
Mit Stand vom 2025Q4 halten 841 Institutionen Anteile an Ionis Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 178.22M, was 110.03% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um 3.25% gestiegen.
Was ist die größte Einnahmequelle von Ionis Pharmaceuticals Inc?
Am FY2020 erzielte das Geschäft mit R&D revenue under collaborative agreements für Ionis Pharmaceuticals Inc den höchsten Umsatz in Höhe von 364.56M, was 49.99% des Gesamtumsatzes entspricht.
